{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001336","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.038844+00:00","generated_at":"2026-05-15T19:46:04.965024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April","bullets":["Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.","Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.","Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.","CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.","CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001336","json":"https://secwatch.observer/filing/0001171843-26-001336.json","markdown":"https://secwatch.observer/filing/0001171843-26-001336.md","text":"https://secwatch.observer/filing/0001171843-26-001336.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/0001171843-26-001336-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/f8k_030326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:46:04.965024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}